Mark W. Rixon

2.2k total citations · 1 hit paper
25 papers, 1.1k citations indexed

About

Mark W. Rixon is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark W. Rixon has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Molecular Biology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark W. Rixon's work include T-cell and B-cell Immunology (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune Cell Function and Interaction (7 papers). Mark W. Rixon is often cited by papers focused on T-cell and B-cell Immunology (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune Cell Function and Interaction (7 papers). Mark W. Rixon collaborates with scholars based in United States, Germany and South Africa. Mark W. Rixon's co-authors include Dominic W. Chung, Earl W. Davie, Stacey R. Dillon, Sherri Mudri, Jane A. Gross, Susan McMillen, Margaret Moore, Kevin P. Foley, Ole Schou and Harald S. Haugen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Blood.

In The Last Decade

Mark W. Rixon

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease

2001 509 citations Jane A. Gross, Stacey R. Dillon et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark W. Rixon United States	13	566	354	289	199	123	25	1.1k
Eva Emmell United States	12	371 0.7×	297 0.8×	175 0.6×	101 0.5×	136 1.1×	18	1.0k
Diane R. Leone United States	16	392 0.7×	494 1.4×	266 0.9×	154 0.8×	47 0.4×	18	1.4k
Ghislaine Bernard France	20	523 0.9×	511 1.4×	81 0.3×	379 1.9×	68 0.6×	28	1.5k
José A. Brieva Spain	24	1.0k 1.8×	348 1.0×	125 0.4×	49 0.2×	194 1.6×	45	1.6k
Cathy Quilici Australia	16	698 1.2×	259 0.7×	71 0.2×	66 0.3×	78 0.6×	18	1.1k
Jacqueline Prieto Sweden	15	574 1.0×	231 0.7×	159 0.6×	90 0.5×	26 0.2×	16	1.1k
Xiaoyan Qiu China	20	525 0.9×	551 1.6×	335 1.2×	63 0.3×	50 0.4×	37	1.1k
Sietse Q. Nagelkerke Netherlands	17	512 0.9×	291 0.8×	381 1.3×	69 0.3×	48 0.4×	34	930
H Mitsui Japan	11	554 1.0×	243 0.7×	75 0.3×	67 0.3×	102 0.8×	15	798
Consuelo Anzilotti United Kingdom	17	389 0.7×	455 1.3×	155 0.5×	64 0.3×	315 2.6×	24	1.1k

Countries citing papers authored by Mark W. Rixon

Since Specialization

Citations

This map shows the geographic impact of Mark W. Rixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Rixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Rixon more than expected).

Fields of papers citing papers by Mark W. Rixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Rixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Rixon. The network helps show where Mark W. Rixon may publish in the future.

Co-authorship network of co-authors of Mark W. Rixon

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Rixon. A scholar is included among the top collaborators of Mark W. Rixon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Rixon. Mark W. Rixon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dillon, Stacey R., Lawrence S. Evans, Katherine E. Lewis, et al.. (2023). Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101). Arthritis & Rheumatology. 75(8). 1344–1356. 7 indexed citations

Maurer, Mark, Katherine E. Lewis, Joseph L. Kuijper, et al.. (2022). The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity. Nature Communications. 13(1). 1790–1790. 20 indexed citations

Dillon, Stacey R., Lawrence S. Evans, Katherine E. Lewis, et al.. (2021). OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER B CELL-RELATED AUTOIMMUNE DISEASES. Annals of the Rheumatic Diseases. 80. 21–21. 3 indexed citations

Levin, Steven D., Lawrence S. Evans, Susan Bort, et al.. (2020). Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains. Frontiers in Immunology. 10. 3086–3086. 9 indexed citations

Swiderek, Kristine M., Stacey R. Dillon, John W. Moore, et al.. (2020). P156 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, DEMONSTRATES EFFICACY IN PATIENT-DERIVED PBMC IN VITRO AND IN AN IN VIVO T CELL TRANSFER MODEL OF CHRONIC INFLAMMATORY BOWEL DISEASE (IBD). Inflammatory Bowel Diseases. 26(Supplement_1). S4–S4. 1 indexed citations

Lu, Jinghua, et al.. (2015). Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proceedings of the National Academy of Sciences. 112(3). 833–838. 121 indexed citations

Maurer, Mark, Ursula Garrigues, Stephen R. Jaspers, et al.. (2012). Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies. mAbs. 4(1). 69–83. 12 indexed citations

Ellsworth, Jeff L., Nels Hamacher, Brandon Harder, et al.. (2010). Generation of a high-affinity Fc receptor by Ig-domain swapping between human CD64A and CD16A. Protein Engineering Design and Selection. 23(4). 299–309. 5 indexed citations

Ellsworth, Jeff L., Nels Hamacher, Brandon Harder, et al.. (2009). Recombinant Soluble Human FcγR1A (CD64A) Reduces Inflammation in Murine Collagen-Induced Arthritis. The Journal of Immunology. 182(11). 7272–7279. 25 indexed citations

10.

Bilsborough, Janine, Ellen G. Chadwick, Sherri Mudri, et al.. (2008). TACI‐Ig prevents the development of airway hyperresponsiveness in a murine model of asthma. Clinical & Experimental Allergy. 38(12). 1959–1968. 13 indexed citations

11.

Gross, Jane A., Stacey R. Dillon, Sherri Mudri, et al.. (2001). TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease. Immunity. 15(2). 289–302. 509 indexed citations breakdown →

12.

Conklin, Darrell, Mark W. Rixon, Rolf Kuestner, et al.. (2000). Cloning and gene expression of a novel human ribonucleoprotein. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1492(2-3). 465–469. 22 indexed citations

13.

Rixon, Mark W., Brian B. Gourlie, D A Kaplan, Jeffrey Schlom, & Peter Mézeš. (1993). Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies.. The Journal of Immunology. 151(11). 6559–6568. 11 indexed citations

14.

Rixon, Mark W., Edith A. S. Harris, & Richard Gelinas. (1990). Expression of the human .gamma.-globin gene after retroviral transfer to transformed erythroid cells. Biochemistry. 29(18). 4393–4400. 11 indexed citations

15.

Rixon, Mark W. & Richard Gelinas. (1988). A Fetal Globin Gene Mutation in ^Aϒ Nondeletion Hereditary Persistence of Fetal Hemoglobin Increases Promoter Strength in a Nonerythroid Cell. Molecular and Cellular Biology. 8(2). 713–721. 6 indexed citations

16.

Rixon, Mark W., et al.. (1988). Gamma gene promoter and enhancer structure in Seattle variant of hereditary persistence of fetal hemoglobin. Blood. 71(4). 1108–1112. 10 indexed citations

17.

Rixon, Mark W., Dominic W. Chung, & Earl W. Davie. (1985). Nucleotide sequence of the gene for the .gamma. chain of human fibrinogen. Biochemistry. 24(8). 2077–2086. 58 indexed citations

18.

Chung, Dominic W., Mark W. Rixon, Benito G. Que, & Earl W. Davie. (1983). CLONING OF FIBRINOGEN GENES AND THEIR cDNA*. Annals of the New York Academy of Sciences. 408(1). 449–456. 20 indexed citations

19.

Rixon, Mark W., Wai‐Yee Chan, Earl W. Davie, & Dominic W. Chung. (1983). Characterization of a complementary deoxyribonucleic acid coding for the .alpha. chain of human fibrinogen. Biochemistry. 22(13). 3237–3244. 70 indexed citations

20.

Chung, Dominic W., Mark W. Rixon, Ross T. A. MacGillivray, & Earl W. Davie. (1981). Characterization of a cDNA clone coding for the beta chain of bovine fibrinogen.. Proceedings of the National Academy of Sciences. 78(3). 1466–1470. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact